Thibaut Kleiner

Thibaut Kleiner is the Director for Policy, Strategy and Outreach at DG Connect. He has worked since 2001 at the European Commission. The first ten years of his career in the Commission were spent in the area of competition policy (merger, antitrust and State aid). He was notably member of the cabinet of Neelie Kroes, Commissioner for Competition, in 2007-2010 and head of unit for State aid coordination in DG Competition. In September 2011, he moved to the digital policy area, as advisor of Vice-President Neelie Kroes, in charge of the Digital Agenda, and supervised Internet policies at large (Internet Governance, cybersecurity, cloud, data). From January 2014 to June 2016, he was head of unit in charge of network technologies (5G and Internet of Things) in DG Connect. From June 2016 to December 2019 he was the deputy head of cabinet of Commissioner Oettinger, in charge of Budget and Human Resources and he then came back to DG Connect to head the unit in charge of Research Strategy and Coordination. An economist by training, Thibaut holds a Master from HEC Paris and a PhD from the London School of Economics.

Dr. Walter C. Copan – Congressional Testimony: The State of U.S. Science and Technology: Ensuring U.S. Global Leadership

On February 5th, 2025, Dr. Walter C. Copan testified before the House Committee on Science, Space, and Technology on the State of U.S. Science and Technology: Ensuring U.S. Global Leadership. Copan, Vice President for Research and Technology Transfer at the Colorado School of Mines, former Director of the National Institute
Read More

(Transcript) Protecting Intellectual Property for National Security: A Conversation with Rep. Nathaniel Moran (R-TX)

This transcript is from a CSIS and LeadershIP event hosted on December 3, 2024. Watch the full video here. John J. Hamre: Good afternoon, everybody. Welcome. We’re delighted to have you here. My name is John Hamre. I’m the president at CSIS. And this is going to be one
Read More

Generic Drugs, Property Rights, and the Orange Book

By Chris Borges Intellectual property (IP) rights secured through patents facilitate the introduction of dozens of new brand-name drugs and hundreds of generic drugs annually in the United States. However, proposals advanced by the Biden administration have mistakenly singled out patents as the cause of high drug prices, potentially harming the dense networks
Read More